- Email: [email protected]
Sa1887 Gastrointestinal Bleeding in Patients With Hemorrhagic Hereditary Telangiectasia: a Cross Sectional Study
index: 2 versus 1; P=0.0084), lower rate of complications (22% versus 60%; p < 0.0001), shorter length of stay (median: 9 versus 13.5 days; p = 0.0016), but higher rate of rebleeding (39% versus 16%; p = 0.012). There was no difference in unadjusted overall 30-day mortality. When adjusting for differences in patient characteristics patients treated with TAE had a lower overall 30-day mortality (OR: 0.30; P = 0.04). CONCLUSION: Transcatheter arterial embolization is associated with lower mortality, lower rate of complications, and lower length of stay compared to surgical hemostasis. TAE seems to be the best first-line treatment in patients with endoscopy-refractory PUB.
Sa1889
Background/Aims:Percutaneous coronary intervention (PCI) is generally performed as therapeutic procedure and requires more than 1 year of antithrombotic treatment in acute coronary syndrome (ACS). However, we often encounter upper gastrointestinal bleeding (UGIB), a serious complication of antithrombotic therapy. The aim of this study was to investigate the incidence and clinical risk factors of UGIB in Korean patients undergoing PCI. Patients and Methods:A total of 3541 patients undergoing PCI between January 2006 and June 2012 were retrospectively analyzed for risk factors associated with UGIB within a year of PCI. Results:UGIB was occurred in 35 patients (0.98%). The univariate analysis suggested that the following factors were associated with UGIB: history of peptic ulcer disease (PUD), male, age of ≥ 65 years (old age), presence of chronic kidney disease (CKD), and the use of anticoagulant. Multivariable logistic regression analysis revealed history of PUD (aOR 8.72; 95%CI 2.79-27.33; p=0.000), male (aOR 3.58; 95%CI: 1.33-9.64; p=0.012), old age (aOR 3.10; 95%CI: 1.39-6.92; p=0.006), presence of CKD (aOR 2.76; 95%CI: 1.17-6.54; p= 0.021), the use of anticoagulant (aOR 4.34; 95%CI: 1.65-11.40; p=0.003) as independent risk factors of UGIB. Conclusion:History of PUD, male, old age, presence of CKD, and use of anticoagulant were the independent risk factors of UGIB.
Sa1887 Gastrointestinal Bleeding in Patients With Hemorrhagic Hereditary Telangiectasia: a Cross Sectional Study Natalia Causada Calo, Maria J. Arguero, María L. Gonzalez, Manuel A. Mahler, Dante Manazzoni, Juan A. De Paula, Marcelo M. Serra Introduction: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with a prevalence of 1:5000. It is characterized by the presence of mucocutaneous telangiectases and arteriovenous malformations that can affect the gastrointestinal (GI) tract and cause gastrointestinal bleeding (GIB). Nearly 80% of HHT patients have GI telangiectases and 25% experience overt GIB. In the setting of iron deficiency anemia and mild epistaxis, the GI tract is a potential source of bleeding. Prevalence of occult and overt GIB, especially in patients with mild epistaxis, has not been fully established. Aims: The main objective was to describe the prevalence of overt and occult GIB in HHT patients. Secondary objectives were to estimate the association between unexplained iron deficiency anemia and overt GIB, and assess quality of life in HHT patients with history of GIB. Methods: Patients from the HHT Unit of the Hospital Italiano de Buenos Aires were included. We defined overt GIB as melena, hematochezia or hematemesis. Iron deficiency anemia in the absence of epistaxis or with a mild severity index (Sadick Grade I epistaxis) was defined as unexplained iron deficiency anemia (UIDA). Occult GIB was defined as UIDA in the absence of overt GIB. Prevalence of occult GIB, overt GIB and UIDA were estimated. Endoscopic location of the lesions was described. The association between UIDA and overt GIB was calculated. Quality of life was assessed by EuroQol visual analog scale. Results: At the time of the study, 146 patients were included in the HHT Unit. Prevalence of GIB was 40.4% (n=59), mean age was 54 years (SD 14.5 y) and 72.9% (n=43) were women. Prevalence of overt and occult GIB was 24.7% (n=36) and 15.8% (n=23), respectively. Vascular malformations were localized mostly in stomach (54.2%) and duodenum (40.7%). Twenty four percent (n= 14) were admitted to the hospital for GIB, 6.8% (n=2) of them to the intensive care unit. Median EuroQol score was 6 (IQR=3) and 8 (IQR=2.25) in patients with and without history of GIB, respectively (p=0.02). Twenty eight percent (n=41) had UIDA. Prevalence of overt GIB was considerably higher in patients with UIDA in comparison to those without it [44% (n= 18) vs. 17% (n=18); p=0.001; OR = 3.78; 95% CI 1.7-8.4]. Discussion: Prevalence of overt GIB in HHT patients was similar to previous studies. Overt GIB was significantly higher among patients with unexplained iron deficiency anemia. Upper endoscopy is a reasonable initial approach in these patients given that most of the lesions were located in the upper GI tract. Patients with history of GIB reported a poorer quality of life. Further research regarding quality of life and diagnostic and therapeutic approaches in HHT patients with GIB are needed.
Sa1890 The Impact of Comorbidities on 30-Day Mortality in Peptic Ulcer Bleeding Daniela Matei, Carmen Cruciat, Bogdan Furnea, Cristina Levi, Ioana Groza, Lidia Puie, Corina Bocsan, Stefan Cristian Vesa, Marcel Tantau Background. Peptic ulcer bleeding (PUB) is the most common cause of upper gastrointestinal bleeding. Despite the introduction of therapeutic endoscopy and acid-suppressive therapy, the mortality has remained stable and is strongly associated with advanced age and presence of severe comorbidity. The aim of the study is to evaluate the comorbidities impact on 30day mortality in peptic ulcer bleeding. Material and method. This is a prospective study that included 204 patients presenting to the emergency department of a tertiary care center with PUB, throughout an 8-month period. We analyzed the following variables with possible influence on the mortality rate: demographic data, clinical parameters (hypotension, tachycardia, the presence and characteristics of hematemesis, the presence of melena or hematochesia), use of NSAIDs , antiplatelets or anticoagulants, the severity of anemia and the need of transfusion, the level of ureea and INR, the endoscopic aspect of the ulcers (high-risk stigmata: active bleeding, visible vessel or adherent clot and low-risk stigmata: a clean-based ulcer or a nonprotuberant pigmented dot, respectively) and comorbidities (no comorbidity, single comorbidity and multiple or severe comorbidity). Comorbidity was defined using the Charlson Index. Results. The patients' mean age was 62.78 year (min 19 years, max 94 years) and 11.76% of them were over 80 years old. Male patients were predominant (68.14%). Thirty-day mortality rate was 9.31%. Comparing the patients who died with the ones that survived we observed the following significant differences: age over 80 years 31.58% vs 9.73% (p=0.015); hypotension 47.37% vs 5.41% (p<0.001); hemoglobin (g/dl) 8.06±2.08 vs 9.91±2.73 (p=0.006); needs for transfusion (blood units) 4 (1;7) vs 1 (0;3) (p=0.001); ureea (mg/dl) 122 (74.65;160) vs 77 (56;114) (p=0.006); high risk of endoscopic lesions 89.47% vs 64.32(p= 0.049); multiple or severe comorbidity (68.42% vs 35.68%) (p=0.017). Three factors were associated, significantly independent with patients' death: the presence of multiple or severe co-morbidities (HR=14.41, 95%CI: 2.31-89.89, p=0.004), age over 80 years (HR=14.94, 95%CI:3.78-59.04, p=0.001) and hypotension (HR=14.96, 95%CI: 4.4150.77, p<0.001). Conclusions. Thirty-day mortality rate was significantly associated with the presence of multiple or severe comorbidities, age over 80 years and hypotension.
Sa1888 Target Level for Hemoglobin Correction in Patients With Acute Non-Variceal Upper Gastrointestinal Bleeding Jae Min Lee, Hoon Jai Chun, Jong Soo Lee, Seung Han Kim, Seung Joo Nam, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yoon Tae Jeen, Hongsik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu, Jong-Jae Park, Sang Woo Lee Background/Aims Acute upper gastrointestinal (GI) bleeding is a common condition encountered in the hospital. But, target level for hemoglobin (Hb) correction is controversial in patients with acute non-variceal GI bleeding. Several studies suggested that restrictive transfusion strategy (Hb threshold of 7 g/dL) showed acceptable outcomes in patients with acute upper GI bleeding, which were also included variceal upper GI bleeding. In this study, we compared the clinical outcomes of different transfusion strategies in the patients with acute non-variceal upper GI bleeding. Methods Retrospective analysis was carried out in the patients with acute non-variceal upper GI bleeding. We also proceeded a prospective study. They were randomly assigned to two groups; Restrictive transfusion group (Target Hb level: over 8 g/dL) or liberal group (Target Hb level: over 10 g/dL). Patients with liver cirrhosis, ischemic heart disease, and cerebrovascular disease were excluded. If patient's Hb level was fallen under target, red blood cell transfusion was performed to correct it. Clinical data were collected and analyzed during 45 days after discharge. Results During a period of 12 months, 139 patients satisfied the criteria in the retrospective study. There was no significant difference in re-bleeding rate between patients with Hb level 8 ~ 10 g/dL and Hb level over 10 g/dL at the day of discharge (11.8% vs. 13.2%). Whereas, Hb levels at 7 days after discharge showed difference (10.4 g/dL vs. 11.4 g/dL; p<0.001), there was no significant difference of outcomes at 45 days after (12.5 g/dL vs. 12.0 g/dL). Increase of Hb level was more dominant in restrictive transfusion group than liberal group (after 7 days, 1.5 g/dL vs. 0.6 g/dL; p=0.002, after 45 days; 3.6 g/dL vs. 1.1 g/dL, p<0.001). In prospective study, we enrolled 63 patients with acute non-variceal upper GI bleeding. We randomly assigned 32 of them to restrictive transfusion group and 31 to liberal transfusion group. Re-bleeding rate showed difference between restrictive transfusion group and liberal transfusion group (15.6% vs. 19.7%). Hb level at 7 days and 45 days after discharge come close during the follow up period. Clinical symptoms (general weakness, dizziness, and others) were not shown significant differences between 2 groups. Conclusion As compared between 2 groups of different target of Hb level, there was not significantly different outcome in patients with acute non-variceal upper GI bleeding. In our study, the results suggest that in patients without severe comorbidity(eg. ischemic heart disease, cerebrovascular disease), a strategy of not performing transfusion until the Hb falls below 8 g/dL is safe and effective approach. We think that Hb level of 8 g/dL for initiating transfusion may be acceptable target in patient with acute non-variceal upper GI bleeding.
Sa1891 The Comparative Effectiveness of Upper Endoscopy, Angiographic Embolization and Surgery in Achieving Hemostasis for Recurrent Non-Variceal Upper Gastrointestinal Bleeding (NVUGIB) Ari Garber, Mazen Albeldawi, Johnathon Markus, Paresh P. Mehta, Rocio Lopez, John J. Vargo, Sunguk Jang Background: Endoscopic therapy for NVUGIB achieves hemostasis in 90% of patients, but up to 20% of patients rebleed. Rebleeding is the most important predictor of mortality, occurring in 6-7% of patients. Current recommendations suggest angiographic embolization when endoscopy has failed, while surgery is typically reserved as a last resort. Nevertheless, optimal management strategies for patients with recurrent GI bleeding after initial endoscopic intervention are lacking. We aim to assess the comparative effectiveness of repeat endoscopic intervention, angiographic embolization and surgery in achieving hemostasis for rebleeding following index endoscopic therapy for NVUGIB. Methods: We retrospectively analyzed consecutive patients who underwent EGD for the initial evaluation of NVUGIB between January 2008 and November 2011. Gastrointestinal bleeding was defined as hematemesis, coffee ground emesis, melena, and hematochezia with confirmation on upper endoscopy. Rebleeding was defined as a GI bleed following index endoscopic therapy within 30 days of initial bleed. The clinical and endoscopic characteristics of patients with rebleeding were reviewed and compared with those of patients without rebleeding: demographics, comorbidities, alcohol use, smoking history, medications, endoscopic findings, therapeutic interventions, serum and hemodynamic parameters, ICU length of stay and mortality. Multivariate cox regression analysis was used to analyze the data. Results: 251 adult patients (mean age 64 ± 13 years, 39% female, 74% Caucasian, BMI 29.5 ± 9.6 kg/m2) underwent EGD for acute NVUGIB. The most common indication was melena (50%). The most common source of bleeding was ulcers (83%), of which 50% were located in the stomach. A total of 123 (49%) patients experienced an episode of recurrent bleeding after an average of 3.5 ± 6.1 days from initial bleed. Most patients only had one rebleeding episode (58%). The median number of rebleeding episodes was 1. Average ICU length of stay was 14.5 ± 16.7
S-321
AGA Abstracts
AGA Abstracts
Clinical Characteristics of Upper Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Single-Center Study Ji Myoung Lee, Sung Uk Lim, Ho-Seok Ki, ChungHwan Jun, Chang-Hwan Park, HyunSoo Kim, Sung-Kyu Choi, Jong-Sun Rew, Seon-Young Park
Sa1889
Background/Aims:Percutaneous coronary intervention (PCI) is generally performed as therapeutic procedure and requires more than 1 year of antithrombotic treatment in acute coronary syndrome (ACS). However, we often encounter upper gastrointestinal bleeding (UGIB), a serious complication of antithrombotic therapy. The aim of this study was to investigate the incidence and clinical risk factors of UGIB in Korean patients undergoing PCI. Patients and Methods:A total of 3541 patients undergoing PCI between January 2006 and June 2012 were retrospectively analyzed for risk factors associated with UGIB within a year of PCI. Results:UGIB was occurred in 35 patients (0.98%). The univariate analysis suggested that the following factors were associated with UGIB: history of peptic ulcer disease (PUD), male, age of ≥ 65 years (old age), presence of chronic kidney disease (CKD), and the use of anticoagulant. Multivariable logistic regression analysis revealed history of PUD (aOR 8.72; 95%CI 2.79-27.33; p=0.000), male (aOR 3.58; 95%CI: 1.33-9.64; p=0.012), old age (aOR 3.10; 95%CI: 1.39-6.92; p=0.006), presence of CKD (aOR 2.76; 95%CI: 1.17-6.54; p= 0.021), the use of anticoagulant (aOR 4.34; 95%CI: 1.65-11.40; p=0.003) as independent risk factors of UGIB. Conclusion:History of PUD, male, old age, presence of CKD, and use of anticoagulant were the independent risk factors of UGIB.
Sa1887 Gastrointestinal Bleeding in Patients With Hemorrhagic Hereditary Telangiectasia: a Cross Sectional Study Natalia Causada Calo, Maria J. Arguero, María L. Gonzalez, Manuel A. Mahler, Dante Manazzoni, Juan A. De Paula, Marcelo M. Serra Introduction: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with a prevalence of 1:5000. It is characterized by the presence of mucocutaneous telangiectases and arteriovenous malformations that can affect the gastrointestinal (GI) tract and cause gastrointestinal bleeding (GIB). Nearly 80% of HHT patients have GI telangiectases and 25% experience overt GIB. In the setting of iron deficiency anemia and mild epistaxis, the GI tract is a potential source of bleeding. Prevalence of occult and overt GIB, especially in patients with mild epistaxis, has not been fully established. Aims: The main objective was to describe the prevalence of overt and occult GIB in HHT patients. Secondary objectives were to estimate the association between unexplained iron deficiency anemia and overt GIB, and assess quality of life in HHT patients with history of GIB. Methods: Patients from the HHT Unit of the Hospital Italiano de Buenos Aires were included. We defined overt GIB as melena, hematochezia or hematemesis. Iron deficiency anemia in the absence of epistaxis or with a mild severity index (Sadick Grade I epistaxis) was defined as unexplained iron deficiency anemia (UIDA). Occult GIB was defined as UIDA in the absence of overt GIB. Prevalence of occult GIB, overt GIB and UIDA were estimated. Endoscopic location of the lesions was described. The association between UIDA and overt GIB was calculated. Quality of life was assessed by EuroQol visual analog scale. Results: At the time of the study, 146 patients were included in the HHT Unit. Prevalence of GIB was 40.4% (n=59), mean age was 54 years (SD 14.5 y) and 72.9% (n=43) were women. Prevalence of overt and occult GIB was 24.7% (n=36) and 15.8% (n=23), respectively. Vascular malformations were localized mostly in stomach (54.2%) and duodenum (40.7%). Twenty four percent (n= 14) were admitted to the hospital for GIB, 6.8% (n=2) of them to the intensive care unit. Median EuroQol score was 6 (IQR=3) and 8 (IQR=2.25) in patients with and without history of GIB, respectively (p=0.02). Twenty eight percent (n=41) had UIDA. Prevalence of overt GIB was considerably higher in patients with UIDA in comparison to those without it [44% (n= 18) vs. 17% (n=18); p=0.001; OR = 3.78; 95% CI 1.7-8.4]. Discussion: Prevalence of overt GIB in HHT patients was similar to previous studies. Overt GIB was significantly higher among patients with unexplained iron deficiency anemia. Upper endoscopy is a reasonable initial approach in these patients given that most of the lesions were located in the upper GI tract. Patients with history of GIB reported a poorer quality of life. Further research regarding quality of life and diagnostic and therapeutic approaches in HHT patients with GIB are needed.
Sa1890 The Impact of Comorbidities on 30-Day Mortality in Peptic Ulcer Bleeding Daniela Matei, Carmen Cruciat, Bogdan Furnea, Cristina Levi, Ioana Groza, Lidia Puie, Corina Bocsan, Stefan Cristian Vesa, Marcel Tantau Background. Peptic ulcer bleeding (PUB) is the most common cause of upper gastrointestinal bleeding. Despite the introduction of therapeutic endoscopy and acid-suppressive therapy, the mortality has remained stable and is strongly associated with advanced age and presence of severe comorbidity. The aim of the study is to evaluate the comorbidities impact on 30day mortality in peptic ulcer bleeding. Material and method. This is a prospective study that included 204 patients presenting to the emergency department of a tertiary care center with PUB, throughout an 8-month period. We analyzed the following variables with possible influence on the mortality rate: demographic data, clinical parameters (hypotension, tachycardia, the presence and characteristics of hematemesis, the presence of melena or hematochesia), use of NSAIDs , antiplatelets or anticoagulants, the severity of anemia and the need of transfusion, the level of ureea and INR, the endoscopic aspect of the ulcers (high-risk stigmata: active bleeding, visible vessel or adherent clot and low-risk stigmata: a clean-based ulcer or a nonprotuberant pigmented dot, respectively) and comorbidities (no comorbidity, single comorbidity and multiple or severe comorbidity). Comorbidity was defined using the Charlson Index. Results. The patients' mean age was 62.78 year (min 19 years, max 94 years) and 11.76% of them were over 80 years old. Male patients were predominant (68.14%). Thirty-day mortality rate was 9.31%. Comparing the patients who died with the ones that survived we observed the following significant differences: age over 80 years 31.58% vs 9.73% (p=0.015); hypotension 47.37% vs 5.41% (p<0.001); hemoglobin (g/dl) 8.06±2.08 vs 9.91±2.73 (p=0.006); needs for transfusion (blood units) 4 (1;7) vs 1 (0;3) (p=0.001); ureea (mg/dl) 122 (74.65;160) vs 77 (56;114) (p=0.006); high risk of endoscopic lesions 89.47% vs 64.32(p= 0.049); multiple or severe comorbidity (68.42% vs 35.68%) (p=0.017). Three factors were associated, significantly independent with patients' death: the presence of multiple or severe co-morbidities (HR=14.41, 95%CI: 2.31-89.89, p=0.004), age over 80 years (HR=14.94, 95%CI:3.78-59.04, p=0.001) and hypotension (HR=14.96, 95%CI: 4.4150.77, p<0.001). Conclusions. Thirty-day mortality rate was significantly associated with the presence of multiple or severe comorbidities, age over 80 years and hypotension.
Sa1888 Target Level for Hemoglobin Correction in Patients With Acute Non-Variceal Upper Gastrointestinal Bleeding Jae Min Lee, Hoon Jai Chun, Jong Soo Lee, Seung Han Kim, Seung Joo Nam, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yoon Tae Jeen, Hongsik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu, Jong-Jae Park, Sang Woo Lee Background/Aims Acute upper gastrointestinal (GI) bleeding is a common condition encountered in the hospital. But, target level for hemoglobin (Hb) correction is controversial in patients with acute non-variceal GI bleeding. Several studies suggested that restrictive transfusion strategy (Hb threshold of 7 g/dL) showed acceptable outcomes in patients with acute upper GI bleeding, which were also included variceal upper GI bleeding. In this study, we compared the clinical outcomes of different transfusion strategies in the patients with acute non-variceal upper GI bleeding. Methods Retrospective analysis was carried out in the patients with acute non-variceal upper GI bleeding. We also proceeded a prospective study. They were randomly assigned to two groups; Restrictive transfusion group (Target Hb level: over 8 g/dL) or liberal group (Target Hb level: over 10 g/dL). Patients with liver cirrhosis, ischemic heart disease, and cerebrovascular disease were excluded. If patient's Hb level was fallen under target, red blood cell transfusion was performed to correct it. Clinical data were collected and analyzed during 45 days after discharge. Results During a period of 12 months, 139 patients satisfied the criteria in the retrospective study. There was no significant difference in re-bleeding rate between patients with Hb level 8 ~ 10 g/dL and Hb level over 10 g/dL at the day of discharge (11.8% vs. 13.2%). Whereas, Hb levels at 7 days after discharge showed difference (10.4 g/dL vs. 11.4 g/dL; p<0.001), there was no significant difference of outcomes at 45 days after (12.5 g/dL vs. 12.0 g/dL). Increase of Hb level was more dominant in restrictive transfusion group than liberal group (after 7 days, 1.5 g/dL vs. 0.6 g/dL; p=0.002, after 45 days; 3.6 g/dL vs. 1.1 g/dL, p<0.001). In prospective study, we enrolled 63 patients with acute non-variceal upper GI bleeding. We randomly assigned 32 of them to restrictive transfusion group and 31 to liberal transfusion group. Re-bleeding rate showed difference between restrictive transfusion group and liberal transfusion group (15.6% vs. 19.7%). Hb level at 7 days and 45 days after discharge come close during the follow up period. Clinical symptoms (general weakness, dizziness, and others) were not shown significant differences between 2 groups. Conclusion As compared between 2 groups of different target of Hb level, there was not significantly different outcome in patients with acute non-variceal upper GI bleeding. In our study, the results suggest that in patients without severe comorbidity(eg. ischemic heart disease, cerebrovascular disease), a strategy of not performing transfusion until the Hb falls below 8 g/dL is safe and effective approach. We think that Hb level of 8 g/dL for initiating transfusion may be acceptable target in patient with acute non-variceal upper GI bleeding.
Sa1891 The Comparative Effectiveness of Upper Endoscopy, Angiographic Embolization and Surgery in Achieving Hemostasis for Recurrent Non-Variceal Upper Gastrointestinal Bleeding (NVUGIB) Ari Garber, Mazen Albeldawi, Johnathon Markus, Paresh P. Mehta, Rocio Lopez, John J. Vargo, Sunguk Jang Background: Endoscopic therapy for NVUGIB achieves hemostasis in 90% of patients, but up to 20% of patients rebleed. Rebleeding is the most important predictor of mortality, occurring in 6-7% of patients. Current recommendations suggest angiographic embolization when endoscopy has failed, while surgery is typically reserved as a last resort. Nevertheless, optimal management strategies for patients with recurrent GI bleeding after initial endoscopic intervention are lacking. We aim to assess the comparative effectiveness of repeat endoscopic intervention, angiographic embolization and surgery in achieving hemostasis for rebleeding following index endoscopic therapy for NVUGIB. Methods: We retrospectively analyzed consecutive patients who underwent EGD for the initial evaluation of NVUGIB between January 2008 and November 2011. Gastrointestinal bleeding was defined as hematemesis, coffee ground emesis, melena, and hematochezia with confirmation on upper endoscopy. Rebleeding was defined as a GI bleed following index endoscopic therapy within 30 days of initial bleed. The clinical and endoscopic characteristics of patients with rebleeding were reviewed and compared with those of patients without rebleeding: demographics, comorbidities, alcohol use, smoking history, medications, endoscopic findings, therapeutic interventions, serum and hemodynamic parameters, ICU length of stay and mortality. Multivariate cox regression analysis was used to analyze the data. Results: 251 adult patients (mean age 64 ± 13 years, 39% female, 74% Caucasian, BMI 29.5 ± 9.6 kg/m2) underwent EGD for acute NVUGIB. The most common indication was melena (50%). The most common source of bleeding was ulcers (83%), of which 50% were located in the stomach. A total of 123 (49%) patients experienced an episode of recurrent bleeding after an average of 3.5 ± 6.1 days from initial bleed. Most patients only had one rebleeding episode (58%). The median number of rebleeding episodes was 1. Average ICU length of stay was 14.5 ± 16.7
S-321
AGA Abstracts
AGA Abstracts
Clinical Characteristics of Upper Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Single-Center Study Ji Myoung Lee, Sung Uk Lim, Ho-Seok Ki, ChungHwan Jun, Chang-Hwan Park, HyunSoo Kim, Sung-Kyu Choi, Jong-Sun Rew, Seon-Young Park